Trial · NCT03131219
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 | Complement Inhibitor Treatment Naïve | Complete TMA response | 77.8 | 95% Confidence Interval 52.4 to 93.6 | percentage of participants |
| Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 | Complement Inhibitor Treatment Naïve | Platelet count normalization | 94.4 | 95% Confidence Interval 72.7 to 99.9 | percentage of participants |
| Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 | Complement Inhibitor Treatment Naïve | LDH normalization | 88.9 | 95% Confidence Interval 65.3 to 98.6 | percentage of participants |
| Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 | Complement Inhibitor Treatment Naïve | ≥ 25% improvement in serum creatinine from baseline | 83.3 | 95% Confidence Interval 58.6 to 96.4 | percentage of participants |
| Time To Complete TMA Response In Complement Inhibitor Treatment-naïve Participants | Complement Inhibitor Treatment Naïve | 30.0 | Inter-Quartile Range 22.0 to 88.0 | days | |
| Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete TMA Response At Week 52 | Complement Inhibitor Treatment Naïve | Complete TMA responder | 0.882 | 95% Confidence Interval 0.636 to 0.985 | proportion of participants |
| Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete TMA Response At Week 52 | Complement Inhibitor Treatment Naïve | Platelet count normalization | 0.882 | 95% Confidence Interval 0.636 to 0.985 | proportion of participants |
| Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete TMA Response At Week 52 | Complement Inhibitor Treatment Naïve | LDH normalization | 1.000 | 95% Confidence Interval 0.805 to 1.000 | proportion of participants |
| Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete TMA Response At Week 52 | Complement Inhibitor Treatment Naïve | ≥25% improvement in serum creatinine from baseline | 1.000 | 95% Confidence Interval 0.805 to 1.000 | proportion of participants |
| Participants Who Do Not Require Dialysis at Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Week 26 | 5 | Participants | |
| Participants Who Do Not Require Dialysis at Weeks 26 and 52 | Eculizumab Experienced | Week 26 | 0 | Participants | |
| Participants Who Do Not Require Dialysis at Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Week 52 | 6 | Participants | |
| Participants Who Do Not Require Dialysis at Weeks 26 and 52 | Eculizumab Experienced | Week 52 | 0 | Participants | |
| Change From Baseline In eGFR At Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Baseline | 22.0 | Full Range 10 to 84 | mL/min/1.73 m^2 |
| Change From Baseline In eGFR At Weeks 26 and 52 | Eculizumab Experienced | Baseline | 99.75 | Full Range 54 to 136.5 | mL/min/1.73 m^2 |
| Change From Baseline In eGFR At Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Change From Baseline at Week 26 | 80.0 | Full Range 0 to 222 | mL/min/1.73 m^2 |
| Change From Baseline In eGFR At Weeks 26 and 52 | Eculizumab Experienced | Change From Baseline at Week 26 | -2.00 | Full Range -94 to 18 | mL/min/1.73 m^2 |
| Change From Baseline In eGFR At Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Change From Baseline at Week 52 | 94.0 | Full Range 10 to 230 | mL/min/1.73 m^2 |
| Change From Baseline In eGFR At Weeks 26 and 52 | Eculizumab Experienced | Change From Baseline at Week 52 | -3.00 | Full Range -20 to 9 | mL/min/1.73 m^2 |
| Participants With Change From Baseline In CKD Stage At Weeks 26 and 52 | Complement Inhibitor Treatment Naïve | Week 26, Improved | 15 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03131219/results